{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:26:19Z","timestamp":1767972379310,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.clml.2022.01.006","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T15:22:15Z","timestamp":1642173735000},"page":"e485-e494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical Characteristics and Survival Outcomes of Primary Effusion Lymphoma: A National Cancer Database Study"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3584-9453","authenticated-orcid":false,"given":"Firas","family":"Baidoun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-1219","authenticated-orcid":false,"given":"Muhamad Alhaj","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-094X","authenticated-orcid":false,"given":"Han W.","family":"Tun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.01.006_bib0001","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/MCP.0000000000000384","article-title":"Primary effusion lymphoma","volume":"23","author":"Arora","year":"2017","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.clml.2022.01.006_bib0002","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1634\/theoncologist.12-5-569","article-title":"Primary effusion lymphoma","volume":"12","author":"Chen","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2022.01.006_bib0003","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2141.2011.08778.x","article-title":"Primary effusion lymphoma in an HIV-negative man","volume":"155","author":"Gandhi","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.01.006_bib0004","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1600-6143.2008.02156.x","article-title":"Pleural primary effusion lymphoma in a renal transplant recipient","volume":"8","author":"Melo","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clml.2022.01.006_bib0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/ajh.10341","article-title":"Combined chemotherapy including high-dose methotrexate in KSHV\/HHV8-associated primary effusion lymphoma","volume":"73","author":"Boulanger","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.01.006_bib0006","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood-2018-03-791426","article-title":"Biology and management of primary effusion lymphoma","volume":"132","author":"Shimada","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.006_bib0007","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00042560-199611010-00003","article-title":"The natural history and molecular heterogeneity of HIV-associated primary malignant lymphomatous effusions","volume":"13","author":"Komanduri","year":"1996","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirology"},{"key":"10.1016\/j.clml.2022.01.006_bib0008","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.5858\/arpa.2012-0294-RS","article-title":"Primary effusion lymphoma","volume":"137","author":"Patel","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clml.2022.01.006_bib0009","article-title":"National cancer database - about the national cancer database","year":"2020","journal-title":"Accessed on Septemeber 8th"},{"key":"10.1016\/j.clml.2022.01.006_bib0010","article-title":"International classification of diseases for oncology (ICD-O) \u20133rd edition","year":"2013","journal-title":"1st revision, 3rd ed."},{"key":"10.1016\/j.clml.2022.01.006_bib0011","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1002\/cncr.30112","article-title":"Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: analysis of the national cancer data base","volume":"122","author":"Olszewski","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.01.006_bib0012","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2003.06.013","article-title":"Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study","volume":"21","author":"Simonelli","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.006_bib0013","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13046-017-0632-z","article-title":"Apigenin, by activating p53 and inhibiting STAT3, modulates the balance between pro-apoptotic and pro-survival pathways to induce PEL cell death","volume":"36","author":"Granato","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.clml.2022.01.006_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/104912","article-title":"Targeting of prosurvival pathways as therapeutic approaches against primary effusion lymphomas: past, present, and future","volume":"2015","author":"Granato","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.clml.2022.01.006_bib0015","doi-asserted-by":"crossref","first-page":"e39945","DOI":"10.1371\/journal.pone.0039945","article-title":"Cross-talk between NFkB and the PI3-kinase\/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis","volume":"7","author":"Hussain","year":"2012","journal-title":"Gallyas F, ed. PLoS One"},{"key":"10.1016\/j.clml.2022.01.006_bib0016","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/hon.2372","article-title":"Clinical characteristics and survival outcome of primary effusion lymphoma: a review of 105 patients","volume":"35","author":"El-Fattah","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2022.01.006_bib0017","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","article-title":"Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large b-cell lymphoma and has implication for bias in clinical trials","volume":"36","author":"Maurer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.006_bib0018","doi-asserted-by":"crossref","unstructured":"Hu Z, Pan Z, Chen W, et\u00a0al. Primary effusion lymphoma: a clinicopathological study of 70 cases. Cancers (Basel). 2021;13:878. doi:10.3390\/cancers13040878","DOI":"10.3390\/cancers13040878"},{"key":"10.1016\/j.clml.2022.01.006_bib0019","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1200\/JCO.2005.07.084","article-title":"Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS","volume":"23","author":"Boulanger","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.006_bib0020","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/00002030-200101260-00023","article-title":"Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy","volume":"15","author":"Hocqueloux","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.clml.2022.01.006_bib0021","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/(SICI)1096-8652(199803)57:3<266::AID-AJH25>3.0.CO;2-7","article-title":"Complete remission of a primary effusion lymphoma with antiretroviral therapy","volume":"57","author":"Oksenhendler","year":"1998","journal-title":"Am J Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022000064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022000064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T13:59:15Z","timestamp":1682949555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022000064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2152265022000064"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.01.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Characteristics and Survival Outcomes of Primary Effusion Lymphoma: A National Cancer Database Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}